Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple Myeloma
| Autor: | Eric Alden Smith, David J. Chung, Susan Bal, Malin Hultcrantz, Urvi A Shah, Ahmet Dogan, Hani Hassoun, Gunjan L. Shah, Nikoletta Lendvai, Heather Landau, Neha Korde, Oscar B Lahoud, Sean M. Devlin, Sham Mailankody, Scott T. Avecilla, Ola Landgren, Mikhail Roshal, Alexander M. Lesokhin, Parastoo B. Dahi, Michael Scordo, Sergio Giralt |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
medicine.medical_specialty Neoplasm Residual Transplantation Autologous Dexamethasone Article Bortezomib chemistry.chemical_compound Autologous stem-cell transplantation Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Autografts Multiple myeloma Lenalidomide Aged Transplantation business.industry Hematopoietic Stem Cell Transplantation Hematology medicine.disease Minimal residual disease Carfilzomib Hematopoietic Stem Cell Mobilization medicine.anatomical_structure chemistry Bone marrow Stem cell business Multiple Myeloma medicine.drug |
| Zdroj: | Biol Blood Marrow Transplant |
| ISSN: | 1523-6536 |
| Popis: | Autologous stem cell transplantation (ASCT) remains the standard of care for transplantation-eligible patients with multiple myeloma (MM). Bortezomib with lenalidomide and dexamethasone (VRD) is the most common triplet regimen for newly diagnosed MM in the United States. Carfilzomib with lenalidomide and dexamethasone (KRD) has shown promising efficacy and may supplant VRD. We compared stem cell yields and autograft minimal residual disease (MRD)-negativity after VRD and KRD induction. Deeper responses (ie, very good partial response or better) were more common with KRD. Precollection bone marrow (BM) cellularity, interval from the end of induction therapy to start of stem cell collection, and method of stem cell mobilization were similar for the 2 cohorts. Days to complete collection was greater with KRD (2.2 days, versus 1.81 days with VRD), which more often required ≥3 days of apheresis. Precollection viable CD34(+) cell content was greater with VRD, as was collection yield (11.11 × 10(6), versus 9.19 × 10(6) with KRD). Collection failure (defined as |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect